Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein (MALS verified)

分子别名（Synonym）

HLA-A*02:01 & B2M & Glypican 3 (FVGEFFTDV)

表达区间及表达系统（Source）

Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein (HLG-H52E5) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Thr 305 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & FVGEFFTDV peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & FVGEFFTDV).

Predicted N-terminus: Gly 25 & Phe

蛋白结构（Molecular Characterization）

Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Tetramer Protein is assembled by biotinylated monomer (HLG-H82E4) and streptavidin.

Biotinylated Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Complex Protein is produced by co-expression of HLA and B2M loaded with Glypican 3 peptide. Biotinylated Human HLA-A*02:01&B2M&Glypican 3 (FVGEFFTDV) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 36.0 kDa and 13.8 kDa. The protein migrates as 42-45 kDa, 15 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素（Endotoxin）

Less than 1.0 EU per μg by the LAL method / rFC method.

纯度（Purity）

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系（QMS）

1. 质量管理体系（ISO, GMP）
2. 质量优势
3. 质控流程